Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure  by Cresci, Sharon et al.
H
c
y
t
F
U
U
‡
P
H
O
H
p
R
I
t
a
B
a
Journal of the American College of Cardiology Vol. 54, No. 5, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PQUARTERLY FOCUS ISSUE: HEART FAILURE Heart Failure and Genetics
Clinical and Genetic Modifiers
of Long-Term Survival in Heart Failure
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Daniel Dries, MD, MPH,‡ Sharon L. R. Kardia, PHD,† Gerald W. Dorn II, MD*
St. Louis, Missouri; Ann Arbor, Michigan; and Philadelphia, Pennsylvania
Objectives This study sought to identify genetic modifiers of -blocker response and long-term survival in heart
failure (HF).
Background Differences in -blocker treatment effect between Caucasians and African Americans with HF have been
reported.
Methods This was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian) enrolled be-
tween 1999 and 2007; 2,039 patients (81.7%) were treated with a -blocker. Each was genotyped for 1-
adrenergic receptor (ADRB1) Arg389Gly and G-protein receptor kinase 5 (GRK5) Gln41Leu polymorphisms,
which are more prevalent among African Americans than Caucasians. The primary end point was survival time
from HF onset.
Results There were 765 deaths during follow-up (median 46 months). -blocker treatment increased survival in Cauca-
sians (log-rank p  0.00038) but not African Americans (log-rank p  0.327). Among patients not taking
-blockers, ADRB1 Gly389 was associated with decreased survival in Caucasians (hazard ratio [HR]: 1.98, 95%
confidence interval [CI]: 1.1 to 3.7, p  0.03) whereas GRK5 Leu41 was associated with improved survival in
African Americans (HR: 0.325, CI: 0.133 to 0.796, p  0.01). African Americans with ADRB1 Gly389Gly GRK5
Gln41Gln derived a similar survival benefit from -blocker therapy (HR: 0.385, 95% CI: 0.182 to 0.813, p 
0.012) as Caucasians with the same genotype (HR: 0.529, 95% CI: 0.326 to 0.858, p  0.0098).
Conclusions These data show that differences caused by -adrenergic receptor signaling pathway gene polymorphisms,
rather than race, are the major factors contributing to apparent differences in the -blocker treatment effect
between Caucasians and African Americans; proper evaluation of treatment response should account for genetic
variance. (J Am Coll Cardiol 2009;54:432–44) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.009i
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teart failure (HF) affects approximately 5 million Ameri-
ans, with over one-half million new cases diagnosed every
ear (1). Abnormalities of cardiac -adrenergic signaling
hat contribute to the pathophysiology of HF include
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Manuscript received March 31, 2009; revised manuscript received May 11, 2009,
ccepted May 14, 2009.ncreased circulating epinephrine levels and down-regulation
r functional uncoupling of cardiotoxic 1-adrenergic re-
eptors (2,3). Accordingly, -blockers, which antagonize
atecholamine-stimulated -adrenergic receptor signaling
n the heart and elsewhere, represent one of the most
mportant nonsurgical therapeutic options for this disease,
educing morbidity and mortality (4,5). There is a class I
ndication for -blocker treatment in HF (6). However,
ndividual responses to -blocker treatment vary widely, and
here is a need to identify nonresponders within the broader
linical group that shows aggregate benefit as well as to
redict responders within groups in which treatment effects
re less clear.
Variability in HF risk and clinical course is objectively
evealed by population surveys and prospective clinical trials
hat have identified ethnic differences in disease incidence,
rogression, and response to specific therapies (7–9). Ac-
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July 28, 2009:432–44 Gene Modifiers of HF Survivalordingly, the American College of Cardiology/American
eart Association guidelines for evaluation and manage-
ent of HF in the adult concluded that “heart failure
rogresses more rapidly in black than white patients” (6).
he mechanisms responsible for these types of differences
ave not been clearly identified, and undoubtedly include
ocial influences, access to care, and the quality of care (10).
ndividual genetic factors may also play a role (11). Evi-
ence is accumulating in support of specific genetic loci that
ontribute to the overrepresentation of other complex dis-
ases, such as hypertension and type 2 diabetes mellitus, in
ndividuals of African heritage (12–16). A genetic or phar-
acogenomic basis for differences in drug effect between
ndividuals of African and European descent also has been
roposed (17), supported by associations between variable
rug clearance and functionally significant polymorphisms
f genes encoding enzymes important for drug metabolism,
ytochrome P450 (CYPB6), and N-acetyltransferase
NAT2) (18–20). Thus, ethnically diverse populations show
ifferences in drug response that may, in part, be caused by
ariations within genes essential to the drug effect.
In evaluating the potential for genetic variation to influ-
nce HF outcome, it is notable that functional polymor-
hisms are common in the genes encoding the -blocker
arget, -adrenergic receptors (ADRB1 and ADRB2), and a
ene that critically regulates -adrenergic receptor signal-
ng, G-protein receptor kinase 5 (GRK5) (21,22). Previous
harmacogenomic studies have proposed that the ADRB1
rg389Gly (23) and GRK5 Gln41Leu (22) polymor-
hisms, both of which are over-represented in African
mericans, may play roles in determining individual clinical
esponses to -blockade in HF. The biological mechanisms
or the effects of both alleles were established by expressing
ecombinant polymorphic proteins in cultured cells and in
ransgenic mice (22,24). However, studies of their impact
n HF outcome in different ethnic groups, and comparisons
f these 2 putative genetic risk factors with standard clinical
isk factors for HF progression, have not been performed.
erein we report the results of a prospective longitudinal
tudy examining the impact of ADRB1 and GRK5 genotype
n -blocker modulation of long-term outcome in subjects
ith systolic HF who presented to the specialized HF/heart
ransplant programs of 2 major U.S. urban medical centers.
ethods
tudy subjects. Subjects presenting to the HF referral
rograms at the University of Cincinnati or the University
f Pennsylvania were prospectively recruited into 1 of 2
oninterventional longitudinal genomics studies of HF
unded by the National Heart, Lung, and Blood Institute
NHLBI) (P50 HL77101 and R01 HL88577). African
merican inclusion at 25% of the total cohort was part of
he study design approved by NHLBI, and subgroup
nalysis of outcomes in Caucasians and African Americans
as pre-specified. Human study protocols were approved by snstitutional review boards of the
niversity of Cincinnati and the
niversity of Pennsylvania. All
ubjects provided written in-
ormed consent. Enrollment cri-
eria were age between 18 and 80
ears and documented systolic
F with a left ventricular ejec-
ion fraction of40%. The study
ecruited 2,460 HF patients, of
hich 711 (29%) were African
merican; 1,783 subjects (1,164
aucasian Americans and 619
frican Americans) were enrolled between 2000 and 2007
n Cincinnati, and 677 subjects (585 Caucasian Americans
nd 92 African Americans) were enrolled in Philadelphia
etween 2003 and 2005. The cohorts were combined to
rovide a sufficient number of African Americans to power
n analysis of racial subgroups. Racial classification was
elf-reported. The study end points were death or cardiac
ransplantation. Median follow-up was 46.3 months. Use of
-blocker was determined by the subjects’ physicians (66%
arvedilol, 24% metoprolol, 10% other -blockers) and
efined as continuous therapy for at least 6 months. Med-
cation usage was confirmed at hospital clinic visits by
ersonal interview. Follow-up data for each study subject
ere obtained at least yearly, either by personal interview, by
ail, or by telephone conversation.
enotyping. Genomic deoxyribonucleic acid (DNA) for
enotyping was isolated and extracted using the Gentra
uregene genomic DNA purification kit (Qiagen, Valencia,
alifornia). The DNA segments containing the region of
nterest were amplified with the polymerase chain reaction
PCR). The PCR primers were designed using Primer3
nline software (25), and pyrosequencing primers were
esigned using the Pyrosequencing SNP Primer Design
ersion 1.01 software (Biotage AB, Uppsala, Sweden).
efore use, PCR primer sequences were screened across the
uman genome using the National Center for Biotechnol-
gy Information Blast program to ensure their specificity for
he gene of interest. The PCR and pyrosequencing were
erformed as previously described (26). Primers and condi-
ions are listed in the Online Table. The GRK5 Gln41Leu
enotyping was performed by pyrosequencing (University
f Cincinnati cohort) or using a Sequenome MassArray
latform (Sequenome, San Diego, California) (University of
ennsylvania cohort) with conservative genotype calls in
9.8% of samples. The ADRB1 Arg389Gly genotyping was
erformed using Assays-on-Demand (Applied Biosystems,
oster City, California) assay number C_8898494_10 ac-
ording to the manufacturer’s directions.
tatistical analysis. Student t tests and chi-square tests
ere used to assess significant differences in variables
etween ethnic groups and between genotype classes within
thnic groups. The Hardy-Weinberg equilibrium was as-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CI  confidence interval
HF  heart failure
HR  hazard ratio
NHLBI  National Heart,
Lung, and Blood Institute
PCR  polymerase chain
reactionessed in each ethnic group separately. The primary out-
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Gene Modifiers of HF Survival July 28, 2009:432–44ome was time to transplantation or all-cause mortality
hrough 350 months. Differences in time from diagnosis to
nd point were assessed using Kaplan-Meier curves and
og-rank tests (27). Relative risks were obtained by Cox
roportional hazards modeling using an additive genetic
odel after adjustment for age at diagnosis and sex. All
nalyses were carried out using the R Statistical Language
28). An alpha level of 0.05 was used to designate
ignificance.
esults
linical characteristics of the study population. Clinical
haracteristics of the HF study cohort, grouped by race, are
hown in Table 1. The 2 racial groups were well matched in
erms of age, height and weight, sex, and severity of left
entricular dysfunction. As has been noted previously
29,30), hypertension, renal dysfunction, and cerebrovascu-
ar events are more common among African Americans with
F, but in this cohort, diabetes was only slightly more
revalent. Coronary artery disease and ischemic cardiomy-
pathy were more common in Caucasians with HF. As
ight be expected at tertiary referral centers specializing in
F, pharmacological treatment of HF was similar between
he 2 ethnic groups, with80% to 85% of subjects receiving
-blocker (approximately two-thirds treated with carve-
linical Characteristics of the Heart Failure Study PopulationTable 1 Clinical Characteristics of the Heart Failure Study Pop
Variable
Combined
n Mean (SD)
Age at enrollment (yrs) 2,440 53.4 (14.1)
Height (inches) 2,498 67.6 (4.2)
Weight (lbs) 2,498 193.3 (50.7)
Ejection fraction (%) 1,911 31.2 (15.3)
Follow-up time (months) 2,421 67.6 (70.4)
%
Heart failure etiology
Ischemic 1,216 48.80
Nonischemic 1,275 51.20
Female 896 35.80
Diabetes 870 35.00
Hypertension 1,591 63.90
Coronary disease 1,312 58.40
Cerebrovascular event 260 12.10
Dyslipidemia 1,269 52.00
Renal insufficiency 592 25.90
-blocker use 2,039 81.70
Carvedilol 1,348 66.00
Metoprolol 488 23.90
Other 206 10.10
ACE inhibitor use 1,896 76.30
ARB use 467 21.60
Aldosterone antagonist use 708 32.20
Statin use 1,216 57.80
AICD 628 27.90
Transplanted 330 13.20CE  angiotensin-converting enzyme; AICD  automatic implantable cardioverter-defibrillator; ARB  ailol, one-fourth with metoprolol, and 10% another agent),
75% to 80% receiving an angiotensin-converting enzyme
ACE) inhibitor, 22% receiving an angiotensin receptor
locker, and slightly more than 30% receiving an aldoste-
one antagonist. (Fewer than 50 subjects in each group were
reated with hydralazine/isosorbide dinitrate.) Similar pro-
ortions of both ethnic groups received automatic im-
lanted defibrillators (24% to 29%). However, only one-half
s many (7%) African Americans underwent cardiac
ransplantation (averaging 74.7 months after diagnosis) as
id Caucasians (15%; averaging 67.3 months after diag-
osis). Average survival time from first objective HF diag-
osis was 79.9 78.1 months (mean SD) for Caucasians,
ompared with 69.8  68.6 months for African Americans
p  0.17). Together, these data demonstrate that this
opulation of HF study subjects recruited from the com-
rehensive HF/heart transplantation programs of 2 metro-
olitan medical schools has similar clinical characteristics
nd ethnic differences as observed in previous large HF trials
1,6,9,29).
The impact of standard clinical risk factors on HF
urvival in the study cohort is shown in Table 2. All of the
nalyses presented in Table 2 are univariate Cox propor-
ional hazards models. Among Caucasians, increasing age,
ypertension, coronary artery disease, and diabetes each
n
Caucasian American African American
n Mean (SD) n Mean (SD)
1,698 54.4 (14.0) 702 51.4 (14.1)
1,746 67.8 (4.2) 710 67.2 (4.3)
1,746 191.8 (48.7) 710 197.7 (55.6)
1,545 31.4 (15.4) 335 30.8 (14.7)
1,682 70.9 (75.3) 699 60.5 (57.0)
% %
894 51.30 304 43.10
849 48.70 402 56.90
555 31.70 323 45.40
585 33.40 272 38.40
998 56.80 591 83.60
924 60.00 372 54.80
150 10.30 106 15.90
907 52.80 354 50.90
355 22.50 233 34.10
1,392 79.80 611 86.20
926 66.50 396 64.60
327 23.50 154 25.10
140 10.10 63 10.30
1,302 74.40 572 80.90
313 21.20 146 22.10
490 32.40 206 31.10
890 59.30 311 53.80
461 29.30 157 24.00
273 15.40 49 6.90ulationgiotensin receptor blocker.
a
t
t
m
f
f
c
f
n
p
a
c
u
h
o

T
n
h
t
h
r
d
c
m
b
t
e
c
w
s
C
c
n

(
l
(
fi
e
s
C
t
t
i
s
0

A

b
s
T
e
e
A
s
e
f
g
g
t
u
A
A
0

t
A
A
0
f
A
A
c
c
d
q
f
p
i
(
G
d
a
c
a
C
H
435JACC Vol. 54, No. 5, 2009 Cresci et al.
July 28, 2009:432–44 Gene Modifiers of HF Survivalpproximately doubled the mortality risk, whereas among
he smaller African-American cohort, only age and hyper-
ension achieved significance as risk factors for increased
ortality, although the clear trend was for all 3 clinical
actors to decrease survival. Male sex was a significant risk
actor among African Americans, but not Caucasians. In
ontrast, the relationship between left ventricular ejection
raction at presentation and long-term clinical outcome was
ot consistent, as previously observed (29). The Cox pro-
ortional hazards models presented in the following sections
re adjusted for age at HF onset and sex. Although other
linical factors were significantly associated with survival
nivariately, including age and sex in the Cox proportional
azards model greatly reduced or eliminated the significance
f these variables’ relationship with survival.
-blocker treatment effects on mortality in HF.
he group mean benefit of -blocker treatment in HF is
ot disputable (6). However, results of individual studies
ave varied, particularly regarding the effects of -blocker
reatment in African Americans (31,32). Factors that may
ave contributed to differing results include under-
epresentation of African Americans in some trials (33),
ifferent effects of -blockers with unique pharmacological
haracteristics (32), and real mechanistic differences in the
agnitude of treatment effect between ethnic groups, as has
een reported with ACE inhibitors versus other vasodilator
herapy (34,35). To determine whether there were differ-
nces in apparent -blocker treatment effect between Cau-
asians and African Americans within our study population,
e examined mortality as a function of -blocker treatment
tatus in the overall HF cohort, and then separately in
aucasians and African Americans. A summary of the
linical characteristics stratified by -blocker and race eth-
icity is given in Table 3. In the combined cohort,
-blocker treatment significantly increased survival time
-blocker–untreated n  455, -blocker–treated n  2,038,
og-rank p  0.00074) (Fig. 1A) and reduced mortality risk
age- and sex-adjusted hazard ratio [HR]: 0.71, 95% con-
dence interval [CI]: 0.566 to 0.887, p  0.003). The
ffects of metoprolol and carvedilol seemed similar (not
hown). When the survival data were analyzed in the
aucasian subgroup, increased survival with -blocker
reatment (-blocker– untreated n  351, -blocker–
linical Factors Affecting Heart Failure SurvivalTable 2 Clinical Factors Affecting Heart Failure Survival
Combined
Variable HR p Value
Age at study entry 1.03 0.0001
Female 0.783 0.019
Diabetes 1.95 6.9E-12
Hypertension 2.53 0.0001
Coronary disease 1.69 4.2E-6
Ejection fraction 25% 0.85 0.11
R  hazard ratio.reated n  1,391, log-rank p  0.00038) (Fig. 1A, top Anset) and reduced risk of death or transplant (age- and
ex-adjusted HR: 0.679, 95% CI: 0.519 to 0.888, p 
.005) were again statistically significant. However, a
-blocker treatment effect on survival was not as clear in the
frican American subgroup (-blocker–untreated n  98,
-blocker–treated n  611, log-rank p  0.327) (Fig. 1A,
ottom inset), with a trend toward reduced risk (age- and
ex-adjusted HR: 0.698, 95% CI: 0.453 to 1.08, p  0.1).
hese data show that the HRs for -blocker treatment
ffect on mortality between the 2 races are similar, but the
ffects did not achieve statistical significance in African
mericans because the CIs are much broader, notwith-
tanding adequate numbers of subjects and experimental
nd points. Therefore, we further examined survival as a
unction of -blocker treatment status in the 2 ethnic
roups by comparing mortality within each treatment
roup. Survival times were not significantly different be-
ween Caucasians and African Americans in -blocker–
ntreated subjects (Fig. 1B) (Caucasian n  351, African
merican n  98, 82.8  69.3 months for African
mericans vs. 71.0  73.4 months for Caucasians, p 
.46, log-rank p  0.5213), whereas among subjects taking
-blockers, African Americans had shorter survival times
han Caucasians (Fig. 1C) (Caucasian n  1,391, African
merican n  611, 66.8  68.4 months in African
mericans vs. 82.2  79.5 months in Caucasians, p 
.057, log-rank p  0.0005). Thus, the mortality benefit
rom -blockade seems greater in Caucasians than African
mericans from these clinical populations.
DRB1 Gly389 in HF. We considered that the broader
onfidence intervals for -blocker treatment effect in Afri-
an Americans might indicate a greater degree of interin-
ividual variability in this subgroup, possibly as a conse-
uence of genetic factors. We further noted that the only 2
unctionally significant -receptor pathway gene polymor-
hisms reported to affect the response to -blocker therapy
n HF are both over-represented in African Americans
23,36). The first reported such polymorphism substitutes
ly for Arg at position 389, within the signal transduction
omain of the major cardiac -blocker target, 1-
drenergic receptors (37). Therefore, we genotyped our
ohort for this polymorphism and examined whether it was
ssociated with a difference in -blocker treatment effect.
Caucasian American African American
HR p Value HR p Value
1.03 0.0001 1.03 2.8E-9
0.812 0.12 0.623 0.007
2.19 3.9E-11 1.27 0.17
2.35 9.1E-12 2.09 0.0034
1.93 9.6E-6 1.42 0.055
0.98 0.87 0.634 0.03llele frequencies of the minor ADRB1 Gly389 allele were
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Gene Modifiers of HF Survival July 28, 2009:432–44.298 in Caucasians and 0.392 in African Americans.
enotypes were in Hardy-Weinberg equilibrium (African
merican p  0.67; Caucasian American p  0.98) and
imilar to the reported allele frequencies in normal subjects
Caucasians, 0.12 to 0.25 and African Americans, 0.23 to
.38, respectively (21,36). Thus, as previously reported,
his allelic variant is more common among African
mericans than Caucasians, but its prevalence within
acial subgroups is similar between HF subjects and
onaffected control subjects, supporting previous conclu-
ions that this polymorphism does not, by itself, modify
he risk of developing HF (38).
Functional allelic variants that are not independent risk
actors for disease may nevertheless modify the course of
hat disease or its response to specific therapies. This may
articularly apply to polymorphisms of -receptor pathway
enes in HF because hyperactivation of cardiac cat-
cholaminergic signaling occurs early in the course of the
isease. In our study cohort, there were no differences in the
linical characteristics of HF subjects stratified by ADRB1
enotype (Table 4). Before adjusting for clinical risk mod-
fiers, the ADRB1 Gly389 polymorphism tended to be
ssociated with decreased HF survival times in subjects not
aking -blockers when examined for the overall cohort
Arg389 homozygous n  543, Gly389 carriers n  597,
og-rank p 0.0587) (Fig. 2A), or separately for Caucasians
Characteristics of Heart Failure Subjects by -BTable 3 Characteristics of Heart Failure Sub
Caucasians
Variables
-Blocker Untreated
(n  351)
-
Age at enrollment (yrs) 52.3
Height (inches) 67.8
Weight (lbs) 179.8
Ejection fraction (%) 32.0
Follow-up (months) 60.5
Heart failure etiology
Ischemic 51.6
Nonischemic 48.4
Female 31.3
Diabetes 37.8
Hypertension 75.5
Coronary disease 42.1‡
Cerebrovascular event 9.6‡
Dyslipidemia 38.1‡
Renal insufficiency 36.5‡
ACE inhibitor use 65.3‡
ARB use 18.5
Aldosterone antagonist use 21.3‡
Statin use 41.0‡
AICD 8.1‡
Transplanted 18.4‡
Achieved end point 45.9‡
Values are % unless otherwise indicated. *p  0.05 versus –blocker–
 0.05 versus –blocker–treated subjects of the same race.
Abbreviations as in Table 1.Arg389 homozygous n  422, Gly389 carriers n  369, cog-rank p  0.0436) (Fig. 2A, top inset), but not in
frican Americans (Arg389 homozygous n  119, Gly389
arriers n  223, log-rank p  0.546) (Fig. 2A, bottom
nset). After adjusting for age and sex, however, the Gly389
ssociation with increase mortality risk in -blocker–
ntreated subjects was clearly significant in the entire cohort
HR: 1.76, 95% CI: 1.09 to 2.85, p  0.02) as well as in
aucasian Americans analyzed as a separate subgroup (HR:
.98, 95% CI: 1.07 to 3.65, p  0.03). (The number of
frican Americans not taking -blockers and carrying the
inor allele [n  34] was insufficient to properly power this
ubgroup analysis.) These results suggest a modest benefit
or being homozygous (wild-type) Arg389 among -block-
r–untreated subjects, as has previously been reported (39).
Among subjects treated with the -blockers carvedilol or
etoprolol (as were approximately 90% of the treated
ubjects in our study), there was no significant association
etween survival and ADRB1 Arg389Gly genotype in the
ntire cohort (Arg389 homozygous n  396, Gly389
arriers n  463, log-rank p  0.7974 [Fig. 2B], age- and
ex-adjusted HR: 0.953, 95% CI: 0.736 to 1.24, p 0.501),
r when ethnic groups were analyzed separately (for Cau-
asian Americans: Arg389 homozygous n  299, Gly389
arriers n  271, log-rank p  0.421 [Fig. 2B, top inset],
djusted HR: 0.884, 95% CI: 0.638 to 1.23, p  0.46; for
frican Americans: Arg389 homozygous n  96, Gly389
r Useby -Blocker Use
African American
r Treated
1,391)
-Blocker Untreated
(n  98)
-Blocker Treated
(n  611)
2.6 47.5 51.6
7.9 67.2 67.0
4.6 197.0 198.0
1.1 32.2 30.6
3.2 70.2 58.6
8.1 64.3* 56.1†
1.9 35.7 43.9
1.9 50.0* 44.7†
8.7 30.6 34.6
4.9 53.7*‡ 57.1†
6.8 54.2‡ 61.4
7.0 15.4 9.2†
3.1 43.6‡ 55.3
3.7 32.2 20.5†
3.4 63.3 77.4†
2.7 20.9 21.5
2.7 24.3‡ 34.0
5.9 50.2‡ 61.6†
6.5 22.4*‡ 31.2†
5.1 39.3*‡ 9.6†
3.8 59.8*‡ 25.3
ted Caucasians. †p  0.05 versus –blocker–treated Caucasians. ‡plockejects
Blocke
(n 
5
6
19
3
7
4
5
3
3
8
5
1
5
3
8
2
3
5
2
2
untreaarriers n 188, log-rank p 0.3928 [Fig. 2B, bottom inset];
a
d
p
G
p
t
G
s
L
c
g
t
o
t
a
H
C
d
t
m
b
p
G
t
g
L
f
d
d
o
L
m
i

n
v
437JACC Vol. 54, No. 5, 2009 Cresci et al.
July 28, 2009:432–44 Gene Modifiers of HF Survivaldjusted HR: 0.813, 95% CI: 0.515 to 1.28, p 0.37). These
ata suggest that the Arg389 ADRB1 genotype does not
redict a treatment effect for carvedilol or metoprolol.
RK5 Leu41 in HF. The second adrenergic signaling
olymorphism reported to affect the response to -blocker
herapy in HF substitutes Leu for Gln at position 41 of
RK5, one of the G-protein receptor kinases that desen-
itize cardiac -adrenergic receptors (22,40). The GRK5
eu41 variant shows greater desensitization than the more
ommon wild-type GRK5 Gln41 (41). For this reason, we
enotyped the HF cohort and examined whether possessing
his polymorphism was associated with any difference in HF
utcome or -blocker treatment effect. Allele frequencies of
he minor GRK5 Leu41 allele were 0.017 for Caucasians
nd 0.231 for African Americans. Genotypes were in
ardy-Weinberg equilibrium (African American p  0.63;
aucasians p  0.39) and are similar to the reported allele
istributions in normal subjects (0.013 and 0.23, respec-
Figure 1 Kaplan-Meier Curves of -Blocker Treatment Effect on
(A) Combined heart failure cohort, stratified by -blocker usage (top inset, Caucas
dashed line  -blocker–treated. (B) Survival of -blocker–untreated heart failure
stratified by race. Solid line  Caucasian; dashed line  African American.ively) (22). Except for slight differences in age at enroll- lent, there were no differences in the clinical characteristics
etween subjects homozygous for wild-type GRK5 Leu41
olymorphism versus those carrying at least 1 polymorphic
RK5 Gln41 allele (Table 4).
In an aggregate analysis of -blocker–untreated subjects,
here was no evidence for an effect of GRK5 Leu41
enotype on HF survival (Gln41 homozygous n  390,
eu41 carriers n  47, log-rank p  0.8211) (Fig. 3A) or
or decreased mortality risk (age- and sex-adjusted HR for
eath: 0.755, 95% CI: 0.399 to 1.43, p  0.39). When the
ata were analyzed according to ethnic group, we found
nly 3 subjects in the Caucasian subgroup that carried a
eu41 allele were not taking -blockers, and achieved the
ortality end point during the study period (Fig. 3A, top
nset). Thus, we are underpowered for this analysis. Among
-blocker–untreated African Americans, however, in which
early equal numbers of subjects carry a GRK5 Leu41 allele
ersus are homozygous Gln41 wild-type, the presence of at
rt Failure Survival
ericans; bottom inset, African Americans). Solid line  -blocker–untreated;
ts, stratified by race. (C) Survival of -blocker–treated heart failure subjects,Hea
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Gene Modifiers of HF Survival July 28, 2009:432–44urvival (Gln41 homozygous n 56, Leu41 carriers n 35,
og-rank p  0.0181) (Fig. 3A, bottom inset), and with a
ignificant decrease in mortality risk after adjustment for age
nd sex (HR: 0.325, 95% CI: 0.133 to 0.796, p  0.01).
Interestingly, when -blocker–treated subjects within the
ohort were analyzed as a whole for consequences of the
RK5 polymorphism, a significant detrimental effect of
RK5 Leu41 was detected (Gln41 homozygous n  1,602,
eu41 carriers n  272, log-rank p  0.0052) (Fig. 3B).
owever, the apparent difference by genotype is actually
ttributable to the general difference in outcome observed
etween -blocker–treated Caucasians and African Amer-
cans (compare Fig. 3B with Fig. 1C) because the Leu41
ariant is 10 times more common among African Ameri-
Figure 2 Kaplan-Meier Curves of ADRB1 Arg/Gly 389 Effect on
(A) -blocker–untreated subjects stratified by ADRB1 389Gly carrier status (top in
subjects stratified by ADRB1 389Gly carrier status (top inset, Caucasian American
carriers.ans and there were only 10 Caucasian subjects that carried dLeu41 allele, were taking -blockers, and reached the
tudy end point (Fig. 3B, top inset). In contrast, among
-blocker treated African-American subjects (in whom
here was roughly equal distribution of homozygous Gln41
ild-type vs. Leu41 carriers), there was no association
etween GRK5 Gln41 polymorphism genotype and HF
utcome (Gln41 homozygous n  317, Leu41 carriers n 
27, log-rank p  0.7166) (Fig. 3B, bottom inset).
F risk profiling using clinical and genetic factors.
enotyping of our study cohort for 2 functional
-adrenergic receptor signaling polymorphisms showed 1
enotype, ADRB1 Arg389, that is associated with signifi-
antly decreased mortality risk in -blocker–untreated Cau-
asians, and another, GRK5 Leu41, that is associated with
rt Failure Survival
aucasian Americans; bottom inset, African Americans). (B) -blocker–treated
tom inset, African Americans). Solid line  Arg/Arg 389; dashed line  Gly 389Hea
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July 28, 2009:432–44 Gene Modifiers of HF Survivalmericans, with no evidence for a multiplicative interaction
etween these ADRB1 and GRK5 variants. We considered
hat these genetic factors might contribute to the apparent
ifferences in HF outcomes and -blocker response ob-
erved between Caucasians and African Americans in our
ohort, and re-examined outcome in subjects matched for
hese 2 polymorphisms, that is, in ADRB1 Gly389Gly
RK5 Gln41Gln individuals. When ADRB1 Gly389Gly
RK5 Gln41Gln patients were analyzed, -blocker treat-
ent significantly increased survival time (-blocker–
ntreated n  110, -blocker–treated n  371, log-rank
 0.00058) (Fig. 4A) and reduced mortality risk (age- and
ex-adjusted HR: 0.530, 95% CI: 0.357 to 0.788, p 
.0017) in the combined cohort. The same was true for
-blocker treatment in Caucasians (-blocker–untreated
 87, -blocker–treated n  256, log-rank p  0.0053,
ig. 4A top inset; age- and sex-adjusted HR: 0.529, 95%
I: 0.326 to 0.858, p  0.0098). When this analysis was
pplied to African Americans without considering geno-
ype, it had failed to show a -blocker treatment effect in
his cohort (Fig. 1A, right inset). However, when the
haracteristics of Heart Failure Subjects by ADRB1 and GRK5 GenTable 4 Characteristics of Heart Failure Subjects by ADRB1 an
Variable
ADRB1
Caucasian African
Gly389
(n  369)
Arg389
(n  422)
Gly389
(n  223)
Age at enrollment (yrs) 51.2 50.5 48.4
Height (inches) 67.9 67.9 67.8
Weight (lbs) 191.1 192.1 204.9
Ejection fraction 32.1 31.0 30.8
Follow-up (months) 79.2 80.0 75.5
Heart failure etiology
Ischemic 50.0 54.7 45.4
Nonischemic 50.0 45.3 54.6
Female 47.1 47.5 31.5
Diabetes 36.4 39.6 29.0
Hypertension 66.1 59.9 86.6
Coronary disease 58.0 60.6 48.2
Cerebrovascular event 16.4 16.0 17.5
Dyslipidemia 56.4 51.1 37.9
Renal insufficiency 35.7 42.3 39.1
-blocker use
Carvedilol 50.7 56.6 57.1
Metoprolol 16.1 13.3 19.3
Other 4.0 3.8 4.2
ACE inhibitor use 81.0 81.3 84.0
ARB use 29.6 24.4 25.7
Aldosterone antagonist use 33.7 33.6 34.6
Statin use 62.5 64.5 50.0
AICD 35.9 35.9 25.5
Transplanted 24.9 26.8 10.9
Achieved end point 49.1 51.7 44.5
alues are % unless otherwise indicated. *p  0.05 versus major allele within same subgroup.
Abbreviations as in Table 1.DRB1 Gly389 GRK5 Gln41Gln subgroup of African 0mericans was analyzed, -blocker treatment enhancement
f survival was evident (-blocker–untreated n  22,
-blocker–treated n  111, log-rank p  0.0373) (Fig. 4A,
ottom inset), as was a significant reduction in mortality risk
age- and sex-adjusted HR: 0.385, 95% CI: 0.182 to 0.813,
 0.012). Survival times were similar in genotype-
atched Caucasian and African-American -blocker–
ntreated subjects (Caucasian n  87, African American
 22, log-rank p  0.2368 [Fig. 4B]; age- and sex-
djusted HR: 1.46, 95% CI: 0.611 to 3.51, p  0.39) and
-blocker–treated subjects (Caucasian n  256, African
merican n  111, log-rank p  0.2283) (Fig. 4C),
lthough there was still a trend toward shorter survival times
n -blocker–treated African Americans after adjusting for
ge and sex (adjusted HR: 1.55, 95% CI: 0.992 to 2.43,
 0.054). Another way to conceptualize the interaction of
enotype and -blocker treatment is to examine the effect of
enotype within treatment class. By comparing the ADRB1
ly389Gly GRK5 Gln41Gln genotype with all other geno-
ypes pooled, we found that genotype had no effect among
-blocker–treated subjects (Caucasians HR: 0.854, p 
K5 Genotype
GRK5
ican Caucasian African American
Arg389
n  119)
Gln41
(n  1,587)
Leu41
(n  53)
Gln41
(n  374)
Leu41
(n  263)
50.1 52.5 46.5* 51.6 45.5*
67.0 67.9 68.0 67.5 67.0
194.7 191.2 191.9 199.9 197.5
34.8 31.4 29.7 33.2 30.2
79.7 73.7 60.3* 63.8 61.8
40.4 49.6 56.6 41.7 42.6
59.6 50.4 43.4 58.3 57.4
32.0 31.6 26.4 43.9 48.3
42.2 32.6 45.3 39.3 33.7
84.7 54.6 60.4 81.7 83.2
40.1 57.7 64.3 51.0 52.6
19.1 10.6 05.7 14.5 17.8
43.9 51.1 56.9 50.4 48.2
42.7 23.1 28.9 39.3 31.1
63.7 54.8 67.9 57.4 55.7
17.0 20.1 11.3 23.3 23.3
4.0 4.2 0 4.3 7.6
86.6 74.5 77.4 80.9 82.1
26.0 21.8 19.5 22.2 22.3
35.0 33.1 44.4 29.3 36.5
46.9 58.2 59.5 53.5 51.2
24.7 30.0 37.8 25.4 25.1
8.5 16.4 18.9 7.2 7.6
39.9 33.6 45.3 30.2 27.5otyped GR
Amer
(.35; African Americans HR: 0.829, p 0.39) but did have
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Gene Modifiers of HF Survival July 28, 2009:432–44significant effect among -blocker–untreated Caucasians
Caucasians HR: 2.09, p  0.02; African Americans: HR:
.77, p  0.19). These data suggest that in this HF
opulation, differences caused by -adrenergic receptor
ignaling pathway gene polymorphisms, rather than race,
re the major factor contributing to apparent differences in
-blocker treatment effect between Caucasians and African
mericans.
iscussion
he major finding of this study is that genetic polymor-
hisms of the major cardiac -blocker target, the 1-
drenergic receptor, and a kinase that terminates its signal-
ng, GRK5, can significantly impact HF outcomes, and that
Figure 3 Kaplan-Meier Curves of GRK5 Gln/Leu 41 Effect on H
(A) -blocker–untreated subjects stratified by GRK5 41Leu carrier status (top inse
jects stratified by GRK5 41Leu carrier status (top inset, Caucasian Americans; bo
carriers.djusting for these gene variants abrogates the apparent athnic differences in -blocker treatment effect on HF
urvival.
In HF patients with similar clinical presentations, some
ill have a more rapid disease course, whereas disease
rogression is less aggressive in others (42,43), and the
enefits of recent advances in pharmacological and mechan-
cal therapies for HF have not been equally shared among all
atient groups. In particular, management of HF remains a
hallenge for the African-American population. African
mericans have a 50% higher prevalence of HF, with earlier
nd more severe onset of disease and decreased survival
9,44). There are many possible reasons for racial differences
n health care outcome, including differences in HF etiol-
gy, clinical risk factors, or management practices, as well as
he absence of pre-specified analysis of African Americans
Failure Survival
casian Americans; bottom inset, African Americans). (B) -blocker–treated sub-
nset, African Americans). Solid line  Gln/Gln 41; dashed line  Leu 41eart
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July 28, 2009:432–44 Gene Modifiers of HF Survivalendency for African Americans to be under-represented in
hese studies (45). Our study was specifically designed to
ave proportional representation of African Americans and
o minimize differences in clinical risk factors and manage-
ent practices that may contribute to ethnic differences in
eart disease. Thus, HF patients were recruited from 2 large
unicipal tertiary referral HF/heart transplant programs,
ffording a consistent standard of care that has been shown
o reduce or eliminate ethnic differences in mortality (46).
he 2 ethnic cohorts were well matched for ventricular
unction, ACE inhibitor and -blocker treatment, and
utomatic implantable cardioverter-defibrillator use. Never-
heless, African Americans had significantly higher mortal-
ty rates, had a less clear response to -blocker therapy, and
nderwent transplantation only one-half as often as Cauca-
ians. For this reason, the end point for these studies was
ll-cause mortality, and our multivariate risk factor analysis
Figure 4 Kaplan-Meier Curves of -Blocker Treatment Effect on
in Subjects Matched for ADRB1 Gly 389 and GRK5 G
(A) Combined heart failure cohort, stratified by -blocker usage (top inset, Caucas
dashed line  -blocker treated. (B) Survival of -blocker–untreated heart failure
stratified by race. Solid line  Caucasian; dashed line  African American.djusted for differences in sex and age. wThe mortality from treated HF exceeds that of most
ancers (47), and -blockers are 1 of only 2 drug classes that
ncrease survival (the other being ACE inhibitors).
-blockers are in general highly effective in prolonging
urvival in HF patients, but interindividual differences in
reatment effect continue to complicate disease manage-
ent. Therefore, our focus in these studies was on 2 critical
omponents of the signaling pathway targeted by
-blockers, the 1-adrenergic receptor itself (48), and
RK5, an abundant kinase in myocardium that terminates
-adrenergic receptor signaling (40,41,49). The 1-
drenergic receptor, encoded by the ADRB1 gene, is the
ajor cardiac target of -blockers. Unique to humans is a
ommon polymorphic variation of ADRB1 encoding either
ly or Arg at amino acid 389, located within the intracel-
ular G-protein coupling domain (23). This region of
1-adrenergic receptor is highly conserved between species,
rt Failure Survival
Homozygous Genotype
ericans; bottom inset, African Americans). Solid line  -blocker untreated;
ts, stratified by race. (C) Survival of -blocker–treated heart failure subjects,Hea
ln 41
ian Am
subjecith the human Gly variant being the only known instance
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Gene Modifiers of HF Survival July 28, 2009:432–44f divergence from Arg at this position. The functional
onsequence of introducing Gly is diminished coupling
etween the 1-adrenergic receptor variant and Gs (50)
nd decreased responsiveness to -blockers in genetic
ouse models (51). Human studies have been inconsistent
s to whether there are meaningful associations between this
olymorphism and HF outcome (24,38,39,52–58). The
ore common Arg389 1-adrenergic receptor shows en-
anced functional coupling, is less prevalent in African
mericans, and is associated with a favorable response to
he experimental -blocker bucindolol, whereas carriers of
he Gly389 minor allele reportedly show no survival benefit
rom bucindolol (23). An investigation of adrenergic recep-
or gene polymorphisms on cardiovascular outcomes in the
oman’s Ischemia Syndrome Evaluation (39) found that
arriers of the Gly389 allele were at increased risk for HF
nd all-cause mortality. The current findings of a trend for
mproved HF survival in Caucasians homozygous for
rg389, and the experimental findings of Akhter et al. (59)
hat Arg389 transgenic mice recover from ischemic insults
aster than Gly389 mice, also suggest a more complex role
or this -receptor variant in primary myocardial disease
han has generally been recognized.
The other polymorphism we evaluated is 10 times more
ommon in African Americans than Caucasian Americans,
ubstituting Leu for Gln at position 41 of GRK5. GRK5
elps to terminate -adrenergic receptor signaling by phos-
horylating and uncoupling agonist-occupied receptors
rom their Gs signal transducers (40,49). Amino acid 41 is
n a putative regulatory domain for the kinase, and (as with
he 1-adrenergic receptor 389 polymorphism) the GRK5
mino acid sequence is conserved at this position across
uman, bovine, mouse, rat, dog, and zebrafish homologs,
xcept for the human variant (22). Compared with the
ild-type GRK5, the Leu41 variant promotes more rapid
gonist-mediated desensitization, phosphorylation, and in-
ernalization of the 1-adrenergic receptor (41), and mimics
-blockers in genetic mouse models (22). In a previous
eport, which is the only report to date of this polymor-
hism in a human study, we described a pharmacogenomic
nteraction with -blockers for the combined end point of
ardiac transplantation or death in a small cohort of African
mericans with HF (22). Here, we have greatly expanded
he number of HF subjects studied, doubling the number of
frican-American study subjects to 711, and compared
utcomes with those of almost 1,800 Caucasians recruited
rom the same 2 academic centers. In so doing, we demon-
trate a significant increase in HF survival in African
mericans carrying at least 1 GRK5 Leu41 allele.
The gene modifier effects for the ADRB1 389 polymor-
hism have greater significance for Caucasians, and the
RK5 41 polymorphism is significant only in African
mericans, but these findings do not necessarily indicate
ifferent disease mechanisms between these ethnic groups.
oth the ADRB1 and GRK5 polymorphisms show signifi-
ant differences in prevalence between populations of Eu-opean and African descent, and natural variations in
olymorphism allele frequency between different ethnic
roups can result in correspondingly different pathological
oles for these genetic events in different study populations.
or example, the 8q24 locus associated with prostate cancer
s associated with a higher prevalence of this disease among
frican Americans not because of a greater individual gene
ffect in African-American individuals, but because the risk
llele occurs with greater frequency in this population, and
hereby contributes to increased incidence (60). Thus, the
ost important aspect of the current results is not what
mpact specific adrenergic signaling pathway polymor-
hisms have on HF, because these effects have been shown
o vary between different populations, with different treat-
ent practices, and in different cardiovascular conditions
24,38,39,52–58). Instead, the take-home message is that
olymorphisms such as these 2 that clearly alter functional
athways in experimental systems have the potential to
roduce variability of disease prognosis and outcome in the
ame manner as clinical risk modifiers. Therefore, proper
valuation of disease risk and treatment response should
ccount for genetic variance, either by matching subjects by
elevant genotype as herein, or by including relevant geno-
ypes in multivariate models.
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